Liminatus Pharma Inc (LIMN)
Liminatus Pharma Inc. is a healthcare company listed on NASDAQ under the ticker LIMN. The company operates as a pre-clinical stage biopharmaceutical business focused on developing novel cancer therapies. Its lead program is CD47, a high-affinity humanized anti-CD47 antibody designed to support CD47-SIRPa blockade and help restore the anti-tumor activity of innate immune cells, while aiming to avoid hemagglutination or hemolysis. Liminatus Pharma was founded in 2018 and is based in La Palma, California. The listed security is common stock.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LIMN
|
$1.79
|
-56.1% Downside
|
Expensive
|
Not available
|
Not available
|
Weak
|
0.0%
|
November 13, 2026
|
16.3x
|
5.467 M
|
3.315 M
|
22.8%
|
68.4%
|
-19.9
|
31.8%
|
